The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Anti-Inflammatory Role of the Murine Formyl-Peptide Receptor 2: Ligand-Specific Effects on Leukocyte Responses and Experimental Inflammation
Open accessAbstract
The human formyl-peptide receptor (FPR)-2 is a G protein-coupled receptor that transduces signals from lipoxin A4, annexin A1, and serum amyloid A (SAA) to regulate inflammation. In this study, we report the creation of a novel mouse colony in which the murine FprL1 FPR2 homologue, Fpr2, has been deleted and describe its use to explore the biology of this receptor. Deletion of murine fpr2 was verified by Southern blot analysis and PCR, and the functional absence of the G protein-coupled receptor was confirmed by radioligand binding assays. In vitro, Fpr2−/− macrophages had a diminished response to formyl-Met-Leu-Phe itself and did not respond to SAA-induced chemotaxis. ERK phosphorylation triggered by SAA was unchanged, but that induced by the annexin A1-derived peptide Ac2–26 or other Fpr2 ligands, such as W-peptide and compound 43, was attenuated markedly. In vivo, the antimigratory properties of compound 43, lipoxin A4, annexin A1, and dexamethasone were reduced notably in Fpr2−/− mice compared with those in wild-type littermates. In contrast, SAA stimulated neutrophil recruitment, but the promigratory effect was lost following Fpr2 deletion. Inflammation was more marked in Fpr2−/− mice, with a pronounced increase in cell adherence and emigration in the mesenteric microcirculation after an ischemia–reperfusion insult and an augmented acute response to carrageenan-induced paw edema, compared with that in wild-type controls. Finally, Fpr2−/− mice exhibited higher sensitivity to arthrogenic serum and were completely unable to resolve this chronic pathology. We conclude that Fpr2 is an anti-inflammatory receptor that serves varied regulatory functions during the host defense response. These data support the development of Fpr2 agonists as novel anti-inflammatory therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neutrophils and immunity: challenges and opportunities
Nathan, C. (2006) · Nature reviews. Immunology · doi:10.1038/nri1785 · Cited by 2,971
Points of control in inflammation
Nathan, C. (2002) · Nature · doi:10.1038/nature01320 · Cited by 2,738
Resolution of inflammation: the beginning programs the end
Serhan, C. N., & Savill, J. (2005) · Nature Immunology · doi:10.1038/ni1276 · Cited by 2,552
Immune cell migration in inflammation: present and future therapeutic targets
Luster, A. D., Alon, R., & von Andrian, U. H. (2005) · Nature Immunology · doi:10.1038/ni1275 · Cited by 1,313
Resolvin E1 and protectin D1 activate inflammation-resolution programmes
Schwab, J. M., Chiang, N., Arita, M., & Serhan, C. N. (2007) · Nature · doi:10.1038/nature05877 · Cited by 1,184
Resolution of in flammation: state of the art, definitions and terms
Serhan, C. N., Brain, S. D., Buckley, C. D., Gilroy, D. W., Haslett, C., O'Neill, L. A. J., Perretti, M., Rossi, A. G., & Wallace, J. L. (2007) · The FASEB Journal · doi:10.1096/fj.06-7227rev · Cited by 1,045 · cited 2×
“cocorticoids may mediate a permissive action in the context of inflammatory resolution (5).”
BackgroundSelf-citationSerhan, C. N. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141647 · Cited by 997
Annexin A1 and glucocorticoids as effectors of the resolution of inflammation
Perretti, M., & D'Acquisto, F. (2009) · Nature Reviews Immunology · doi:10.1038/nri2470 · Cited by 915
Self-citationYe, R. D., Boulay, F., Wang, J. M., Dahlgren, C., Gerard, C., Parmentier, M., Serhan, C. N., & Murphy, P. M. (2009) · Pharmacological Reviews · doi:10.1124/pr.109.001578 · Cited by 764
Mast Cells: A Cellular Link Between Autoantibodies and Inflammatory Arthritis
Lee, D. M., Friend, D. S., Gurish, M. F., Benoist, C., Mathis, D., & Brenner, M. B. (2002) · Science · doi:10.1126/science.1073176 · Cited by 750
Cited by
Neutrophils, from Marrow to Microbes
Borregaard, N. (2010) · Immunity · doi:10.1016/j.immuni.2010.11.011 · Cited by 1,573
Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications
Felger, J. C., & Lotrich, F. E. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.04.060 · Cited by 1,180
Specialized pro-resolving mediators: endogenous regulators of infection and inflammation
Basil, M. C., & Levy, B. D. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2015.4 · Cited by 791
Inflammation and its Resolution as Determinants of Acute Coronary Syndromes
Libby, P., Tabas, I., Fredman, G., & Fisher, E. A. (2014) · Circulation Research · doi:10.1161/circresaha.114.302699 · Cited by 521
Sack, G. H. (2018) · Molecular Medicine · doi:10.1186/s10020-018-0047-0 · Cited by 499
Novel Lipid Mediators and Resolution Mechanisms in Acute Inflammation
Serhan, C. N. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.100322 · Cited by 421
Novel Lipid Mediators Promote Resolution of Acute Inflammation: Impact of Aspirin and Statins
Spite, M., & Serhan, C. N. (2010) · Circulation Research · doi:10.1161/circresaha.110.223883 · Cited by 365
Patrolling Alveolar Macrophages Conceal Bacteria from the Immune System to Maintain Homeostasis
Neupane, A. S., Willson, M., Chojnacki, A. K., Vargas E Silva Castanheira, F., Morehouse, C., Carestia, A., Keller, A. E., Peiseler, M., DiGiandomenico, A., Kelly, M. M., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.020 · Cited by 348
Emerging role of 12/15-Lipoxygenase (ALOX15) in human pathologies
Singh, N. K., & Rao, G. N. (2019) · Progress in Lipid Research · doi:10.1016/j.plipres.2018.11.001 · Cited by 345
Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis
Huang, J., Fu, X., Chen, X., Li, Z., Huang, Y., & Liang, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.686155 · Cited by 340
De Santo, C., Arscott, R., Booth, S., Karydis, I., Jones, M., Asher, R., Salio, M., Middleton, M., & Cerundolo, V. (2010) · Nature Immunology · doi:10.1038/ni.1942 · Cited by 304
Hellmann, J., Tang, Y., Kosuri, M., Bhatnagar, A., & Spite, M. (2011) · The FASEB Journal · doi:10.1096/fj.10-178657 · Cited by 302
Cooray, S. N., Gobbetti, T., Montero-Melendez, T., McArthur, S., Thompson, D., Clark, A. J. L., Flower, R. J., & Perretti, M. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1308253110 · Cited by 299
Self-citationResolution of Acute Inflammation in the Lung
Levy, B. D., & Serhan, C. N. (2014) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021113-170408 · Cited by 298
Resolvin D1 Receptor Stereoselectivity and Regulation of Inflammation and Proresolving MicroRNAs
Krishnamoorthy, S., Recchiuti, A., Chiang, N., Fredman, G., & Serhan, C. N. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2012.01.028 · Cited by 283
The role of non-resolving inflammation in atherosclerosis
Kasikara, C., Doran, A. C., Cai, B., & Tabas, I. (2018) · Journal of Clinical Investigation · doi:10.1172/jci97950 · Cited by 266
Pro-resolving lipid mediators: regulators of inflammation, metabolism and kidney function
Brennan, E., Kantharidis, P., Cooper, M. E., & Godson, C. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-021-00454-y · Cited by 262
Resolvins suppress tumor growth and enhance cancer therapy
Sulciner, M. L., Serhan, C. N., Gilligan, M. M., Mudge, D. K., Chang, J., Gartung, A., Lehner, K. A., Bielenberg, D. R., Schmidt, B., Dalli, J., et al. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20170681 · Cited by 256
Self-citationUpdate on leukotriene, lipoxin and oxoeicosanoid receptors: IUPHAR Review 7
Bäck, M., Powell, W. S., Dahlén, S., Drazen, J. M., Evans, J. F., Serhan, C. N., Shimizu, T., Yokomizo, T., & Rovati, G. E. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12665 · Cited by 217
Bozinovski, S., Uddin, M., Vlahos, R., Thompson, M., McQualter, J. L., Merritt, A.-S., Wark, P. A. B., Hutchinson, A., Irving, L. B., Levy, B. D., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1109382109 · Cited by 163
The role of the FPR2/ALX receptor in atherosclerosis development and plaque stability
Petri, M. H., Laguna-Fernández, A., Gonzalez-Diez, M., Paulsson-Berne, G., Hansson, G. K., & Bäck, M. (2015) · Cardiovascular Research · doi:10.1093/cvr/cvu224 · Cited by 125
Aspirin‐triggered lipoxin A4 inhibits atherosclerosis progression in apolipoprotein E−/− mice
Petri, M. H., Laguna‐Fernandez, A., Arnardottir, H., Wheelock, C. E., Perretti, M., Hansson, G. K., & Bäck, M. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13707 · Cited by 120
Self-citationPetri, M. H., Laguna-Fernandez, A., Tseng, C.-N., Hedin, U., Perretti, M., & Bäck, M. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.11.010 · Cited by 60
Self-citationBuss, N. A. P. S., Gavins, F. N. E., Cover, P. O., Terron, A., & Buckingham, J. C. (2015) · The FASEB Journal · doi:10.1096/fj.14-268375 · Cited by 23
Self-citation
Metadata
- Authors
- Dufton, N., Hannon, R., Brancaleone, V., Dalli, J., Patel, H. B., Gray, M., D’Acquisto, F., Buckingham, J. C., Perretti, M., & Flower, R. J.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-03-01
- Volume
- 184
- Issue
- 5
- Pages
- 2611-2619
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2128829928
- Cited by
- 302
- References
- 66
- FWCI
- 11.11
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.